SCHEMBL1997109

SCHEMBL1997109

Nc1cc(Cl)cc(Oc2nc3c(Cl)cccc3s2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
PDE10A Q9Y233 1/20 0.50
ALDH1A1 P00352 4/20 0.43
MAPT P10636 3/20 0.43
HPGD P15428 2/20 0.43
GAA P10253 2/20 0.43
KMT2A Q03164 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
MAPK1 P28482 1/20 0.43
PSMB8 P28062 1/20 0.40
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CTSD P07339 1/20 0.35
NPC1 O15118 1/20 0.35
F2RL3 Q96RI0 1/20 0.35
POLA1 P09884 1/20 0.33
NR4A2 P43354 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2003772 0.87 ALDH1A1 (0.48) LMNAPDE10AALDH1A1MAPTHPGD
SCHEMBL2004646 0.85 ALDH1A1 (0.52) LMNAALDH1A1MAPTHPGDGAA
SCHEMBL1998464 0.82 LMNA (0.54) LMNAPDE10AALDH1A1MAPTHPGD
SCHEMBL12568205 0.81 CYP1A2 (0.49) ALDH1A1MAPTKMT2AMEN1RAB9A
SCHEMBL2000944 0.76 LOXL2 (0.46) ALDH1A1MAPTGAAKMT2AMEN1
SCHEMBL2002218 0.76 APP (0.47) LMNAALDH1A1MAPTGAAKMT2A
SCHEMBL2002248 0.75 RAB9A (0.49) LMNAALDH1A1MAPTHPGDGAA
SCHEMBL2002000 0.73 GFER (0.49) LMNAALDH1A1MAPTHPGDGAA
SCHEMBL2000513 0.73 PPARG (0.48) CYP3A4
SCHEMBL2000936 0.73 LCK (0.42) LMNAALDH1A1MAPTHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960408-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2011-06-14 US disclosed
US-7601841-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2009-10-13 US disclosed
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. (US) 2009-09-03 US disclosed
EP-1296967-B1 BENZOTHIAZOLYL PPAR-GAMMA MODULATORS AMGEN INC (US) 2006-05-31 EP disclosed
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC 2004-09-09 US disclosed
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC. 2003-09-11 US disclosed
US-6583157-B2 Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders TULARIK INC. 2003-06-24 US disclosed
EP-1296967-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS Tularik Inc. (US) 2003-04-02 EP disclosed
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. 2002-11-14 US disclosed
WO-2002000633-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS TULARIK INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD LMNA 3127/4885PDE10A 2233/4885ALDH1A1 3157/4885
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD LMNA 3127/4885PDE10A 2233/4885ALDH1A1 3157/4885
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARA, PPARG, PPARD LMNA 3127/4885PDE10A 2233/4885ALDH1A1 3157/4885
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARG, PPARA, PPARD LMNA 3380/4885PDE10A 2911/4885ALDH1A1 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.